Enterprise Value

205.3B

Cash

14.07B

Avg Qtr Burn

N/A

Short % of Float

0.22%

Insider Ownership

0.00%

Institutional Own.

6.93%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

ABL001/SCEMBLIX Details
Chronic myelomonocytic leukemia, Blood cancer, Cancer, Leukemia

Phase 3

Data readout

Atrasentan Details
Kidney disease, Glomerular diseases, IgA nephropathy

Phase 3

Data readout

Lutathera® Details
Gastroenteropancreatic neuroendocrine tumors, Cancer

Phase 3

Update

Atrasentan Details
Glomerular diseases, Kidney disease

Phase 2

Data readout

CHK-336 Details
Primary hyperoxaluria

Phase 1

Update